InMed Pharmaceuticals (NasdaqCM:INM) 2025 Conference Transcript

InMed Pharmaceuticals Conference Call Summary Company Overview - Company Name: InMed Pharmaceuticals (NasdaqCM: INM) - Industry: Pharmaceutical drug development - Focus: Proprietary small molecule drug candidates targeting CB1 and CB2 receptors [2][3] Key Drug Development Programs 1. INM-901 for Alzheimer's Disease - Target: Alzheimer's disease affecting up to 7.2 million Americans [5] - Preclinical data shows: - Statistically significant reduction in neuroinflammation [6] - Improvement in neuron growth and cognitive functions [7] - Ability to cross the blood-brain barrier [6] - Multiple mechanisms of action including neuroprotection and reduction of amyloid beta [8][10] - Long-term studies indicate improved behavior and cognition in animal models [11] 2. INM-089 for Dry Age-Related Macular Degeneration (AMD) - Target: Dry AMD affecting approximately 19.8 million Americans [16] - Mechanism: Preserves retinal function and heals damaged photoreceptor cells [17][18] - Delivery method: Injection into the eye [18] 3. INM-755 for Epidermolysis Bullosa (EB) - Focus: Cannabinol cream for chronic itch in EB patients [19] - Phase two clinical trial showed 66% of patients experienced clinically meaningful improvement in chronic itch [20] Financial Overview - Cash Position: $9.3 million as of September 30, providing approximately one year of runway [25] - Market Capitalization: Approximately $5.6 million [25] - Shares Outstanding: 4.2 million, fully diluted 6.7 million [25] Strategic Initiatives - Seeking partnerships for funding phase three trials, particularly for INM-755 [21] - Continuing to explore strategic partnerships to expedite drug development [22][23] - Focus on advancing INM-901 and INM-089 towards IND filings [26] Future Catalysts - Identifying strategic partners for drug development [30] - Presenting positive data at scientific conferences to attract interest [31] - Continued progress in preclinical studies for both INM-901 and INM-089 [32] Additional Insights - The company emphasizes the importance of addressing neuroinflammation in Alzheimer's and other diseases [12][28] - The leadership team is experienced in drug development, which is seen as a key strength [3][24] - The company maintains a clean balance sheet with no debt, allowing for focused investment in R&D [25]